Clearbridge Investments LLC Has $387.34 Million Holdings in argenx SE (NASDAQ:ARGX)

Clearbridge Investments LLC grew its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 6.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 629,828 shares of the company's stock after buying an additional 40,330 shares during the quarter. Clearbridge Investments LLC owned approximately 1.04% of argenx worth $387,344,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its stake in shares of argenx by 28.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company's stock worth $1,875,000 after purchasing an additional 768 shares during the last quarter. Cerity Partners LLC increased its position in argenx by 20.4% during the third quarter. Cerity Partners LLC now owns 3,273 shares of the company's stock worth $1,774,000 after buying an additional 555 shares during the last quarter. Daiwa Securities Group Inc. increased its position in argenx by 55.6% during the third quarter. Daiwa Securities Group Inc. now owns 1,315 shares of the company's stock worth $712,000 after buying an additional 470 shares during the last quarter. Bank of Montreal Can lifted its position in shares of argenx by 9.4% in the third quarter. Bank of Montreal Can now owns 8,307 shares of the company's stock worth $4,453,000 after buying an additional 714 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of argenx by 11.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 61,586 shares of the company's stock worth $33,385,000 after acquiring an additional 6,151 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

Remove Ads

argenx Stock Performance

Shares of NASDAQ:ARGX traded up $5.55 on Thursday, hitting $589.17. The stock had a trading volume of 428,492 shares, compared to its average volume of 293,938. The company has a market capitalization of $35.80 billion, a price-to-earnings ratio of -669.51 and a beta of 0.60. The firm's 50 day moving average price is $624.55 and its 200-day moving average price is $602.58. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, sell-side analysts predict that argenx SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

ARGX has been the topic of a number of recent analyst reports. William Blair reissued an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Robert W. Baird boosted their price objective on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Truist Financial reiterated a "buy" rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. JMP Securities upped their price target on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, Wells Fargo & Company lifted their price objective on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.